Literature DB >> 17318112

Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006.

.   

Abstract

Nephrogenic fibrosing dermopathy (NFD) causes thickening and hardening of the skin, often in the extremities, and occurs in patients with underlying renal disease. The skin lesions can progress rapidly, sometimes leading to joint immobility and the inability to walk. In May 2006, nephrologists at hospital A in St. Louis, Missouri, reported to CDC and the Missouri Department of Health and Senior Services (MoDHSS) a cluster of NFD among patients treated in their dialysis units. CDC and MoDHSS conducted an investigation to determine the number of affected patients and identify risk factors for NFD. Thirty-three patients with NFD were identified in St. Louis, 28 of whom had been treated at hospital A. A matched case-control study was conducted at the hospital. This report summarizes the preliminary results of that study, which indicated that exposure to gadolinium-containing contrast agents during magnetic resonance imaging (MRI) studies was independently associated with NFD. Clinicians should be aware of the potential for NFD, and when possible, should avoid use of gadolinium-containing contrast agents in patients with advanced renal disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318112

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  21 in total

1.  [Nephrogenic systemic fibrosis. Medical detective work in the 21st century].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

2.  Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices.

Authors:  Khaled Abdel-Kader; Priti R Patel; Alexander J Kallen; Ronda L Sinkowitz-Cochran; Warren K Bolton; Mark L Unruh
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 8.237

3.  Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.

Authors:  B J Edwards; A E Laumann; B Nardone; F H Miller; J Restaino; D W Raisch; J M McKoy; J A Hammel; K Bhatt; K Bauer; A T Samaras; M J Fisher; C Bull; E Saddleton; S M Belknap; H S Thomsen; E Kanal; S E Cowper; A K Abu Alfa; D P West
Journal:  Br J Radiol       Date:  2014-10       Impact factor: 3.039

4.  Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.

Authors:  Josef A Schroeder; Christian Weingart; Brigitte Coras; Ingrid Hausser; Stephan Reinhold; Matthias Mack; Volker Seybold; Thomas Vogt; Bernhard Banas; Ferdinand Hofstaedter; Bernhard K Krämer
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

5.  Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.

Authors:  Javier Perez-Rodriguez; Shenghan Lai; Benjamin D Ehst; Derek M Fine; David A Bluemke
Journal:  Radiology       Date:  2009-02       Impact factor: 11.105

6.  Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.

Authors:  Robert F Reilly
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

Review 7.  Nephrogenic systemic fibrosis: an emerging entity.

Authors:  Sandip K Saxena; Manjuri Sharma; Mital Patel; Dimitrios Oreopoulos
Journal:  Int Urol Nephrol       Date:  2008-04-17       Impact factor: 2.370

Review 8.  Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.

Authors:  Jeffrey G Penfield
Journal:  Pediatr Nephrol       Date:  2008-06-10       Impact factor: 3.714

Review 9.  Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.

Authors:  Gautam Bhave; Julia B Lewis; Sam S Chang
Journal:  J Urol       Date:  2008-07-17       Impact factor: 7.450

Review 10.  Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity.

Authors:  Derrick J Todd; Jonathan Kay
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.